Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss hope? study tests latanoprost acid in women

NCT ID NCT07412587

Symptom relief Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether applying a cosmetic ingredient called latanoprost acid to the scalp could improve hair growth in women aged 18-60 with female pattern hair loss or chronic telogen effluvium. Twenty-nine women used one of three strengths of the product daily for six months. The main goal was to see if hair count in a small area increased from the start to the end of the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jul 2015

Finished

Jul 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Female participants aged 18-60 years * Diffuse scalp hair loss consistent with female pattern hair loss (FPHL), Ludwig grade I-III, or chronic telogen effluvium * Willingness to comply with all study procedures Exclusion Criteria * Recent use of other hair-growth treatments * Active dermatologic conditions affecting the scalp (active scalp dermatoses) * Significant uncontrolled medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia (AGA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia telogen effluvium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia (AGA) Female pattern hair loss, androgenic alopecia Telogen effluvium

More trials for these conditions

Other studies related to the condition(s) this trial covers.